检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:韩雨[1] 于芹超[1] 曹延炜[1] 王永华[1] 岳德志
出 处:《中华泌尿外科杂志》2015年第10期765-767,共3页Chinese Journal of Urology
摘 要:目的:探讨病理亚分期在T1G3膀胱尿路上皮癌患者预后评价中的意义以及T1me(T1-微浸润和T1-广泛浸润)亚分期系统作为T1G3患者亚分期方法的可行性。方法选择原发T1G3膀胱尿路上皮癌患者87例,其中56例患者的基础资料、病理阅片及随访完整。按照T1me分期法,将56例T1G3膀胱尿路上皮癌患者经尿道膀胱肿瘤电切术后获得的病理标本分为T1m期17例(A组)和T1e期39例(B组),然后分析患者的预后情况。基础资料比较采用χ2检验,5年无复发生存率、5年无进展生存率比较采用Kaplan-Meier生存分析及Log-rank检验。结果两组患者年龄、肿瘤大小、是否多发、膀胱灌注治疗等方面比较差异均无统计学意义(P>0.05)。5年无复发生存率(P=0.037)、5年无进展生存率(P=0.045)比较差异均有统计学意义,T1m期患者预后优于T1e期患者。结论病理亚分期是判断原发T1G3膀胱尿路上皮癌患者预后的重要因素。T1me分期法作为T1G3膀胱尿路上皮癌病理亚分期的分期方法客观、实用、易行。Objective To evaluate the impact of sub-stage on the clinical prognosis of T 1 G3 and evaluate the feasibility of the T1me system in pT1G3 sub-staging.Methods The clinical data,pathological specimen and follow-up data were collected from 56 patients out of 87 patients diagnosed with initial high-grade T1 bladder urothelial carcinoma .The patients were divided into Group A [ T1-microinvasive (T1m),17 cases] and group B [T1-extensive-invasive (T1e),39 cases] according to pathological evaluation after transurethral resection.Clinical parameters were analyzed with Chi-square test,and recurrence-free and progression free survival were obtained by Kaplan-Meier analysis and Log-rank test.Results Age,tumor size,number and intravesical instilled medication showed no significant differences between the 2 groups ( P〉0.05 ) .There were significant differences of 5-year recurrence-free rate ( P =0.037 ) and progression-free survival rate ( P =0.045 ) between the 2 groups, and the prognosis of group A was significantly better than that of group B .Conclusion The pathological sub-stage is an important predictor in initial high-grade T1 bladder urothelial carcinoma patients , and the T1me system is objective and feasible.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222